#China #LabConnect #Clinical Trials #Wuxi

LabConnect Enhances Global Network with New Wuxi Facility

LabConnect, a leading provider of technology-driven central laboratory services for clinical trials, has recently opened a new laboratory facility in Wuxi, China. This expansion reflects the company's commitment to meeting the evolving needs of global clinical trials as they become more complex and widespread across various regions.

The new facility in Wuxi serves a pivotal role as the company responds to sponsors seeking integrated testing, logistics, and data oversight across diverse geographical settings. Alongside LabConnect's existing laboratory capabilities in Australia, the expansion allows the company to provide robust support for multi-regional clinical trials, aiding pharmaceutical, biotechnology, and clinical research organizations throughout the Asia-Pacific region in expanding their research programs globally.

Integrated into LabConnect's global infrastructure, the Wuxi facility enables study teams to operate seamlessly across regions, offering unified data management, continuous operational oversight, and advanced sample logistics and handling procedures. This innovative approach emphasizes LabConnect's ability to streamline operations for its clients, making it easier for them to manage their clinical trials.

The facility was developed in partnership with Teddy Laboratory, which is now a part of Frontage Laboratories. This collaboration combines local laboratory expertise from Teddy with LabConnect's overarching global central laboratory services, leveraging technological advancements to ensure efficient operations.

Wes Wheeler, CEO of LabConnect, highlighted the company's ongoing investment in developing the necessary global services to support current and future clinical research. He stated, "We are proud to provide capabilities based in China and a global network of services that support both multinational pharmaceutical and biotechnology companies entering China, as well as Chinese companies expanding into international markets."

The Wuxi facility is set to support a variety of clinical trial services, including customized kit construction, advanced sample tracking and logistics, and biorepository services. All offerings are crafted to meet international regulatory standards, adding to LabConnect's strong reputation in the field.

The grand opening event, which took place in Wuxi's Xinwu district, featured a ribbon-cutting ceremony, guided laboratory tours, and presentations showcasing LabConnect's technological approach to central laboratory services. The event was attended by representatives from LabConnect, Teddy Laboratory, government officials, and members of the regional clinical research community.

With the addition of the Wuxi site, LabConnect now operates eight global locations, providing sponsors and CROs with the convenience of relying on a single partner for central laboratory services across studies of varying sizes and geographical complexities. This strategic expansion not only emphasizes LabConnect's pivotal role in the clinical trial ecosystem but also showcases its dedication to adopting advanced technologies in support of crucial research endeavors.

About LabConnect

LabConnect is a global provider of technology-driven central laboratory services and functional service provider solutions for the pharmaceutical, biotechnology, and contract research organizations. The company connects laboratories, logistics, technology, and scientific expertise through a decentralized laboratory network model to provide integrated solutions for clinical trials worldwide. For more information about LabConnect, visit www.labconnect.com.